BSE
INDRAMEDCO

INDRAPRASTHA MEDICAL CORP.LTD.

Medical Care Facilities
Healthcare

Prices are adjusted according to historical splits.

INDRAPRASTHA MEDICAL CORP.LTD. Stock Price

Vitals

Today's Low:
₹159
Today's High:
₹171.95
Open Price:
₹168.65
52W Low:
₹56.651
52W High:
₹116
Prev. Close:
₹167
Volume:
26237

Company Statistics

Market Cap.:
₹10.20 billion
Book Value:
41.311
Revenue TTM:
₹10.99 billion
Operating Margin TTM:
10.14%
Gross Profit TTM:
₹3.78 billion
Profit Margin:
7.84%
Return on Assets TTM:
13.7%
Return on Equity TTM:
24.44%

Company Profile

INDRAPRASTHA MEDICAL CORP.LTD. had its IPO on under the ticker symbol INDRAMEDCO.

The company operates in the Healthcare sector and Medical Care Facilities industry. INDRAPRASTHA MEDICAL CORP.LTD. has a staff strength of 0 employees.

Stock update

Shares of INDRAPRASTHA MEDICAL CORP.LTD. opened at ₹168.65 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹159 - ₹171.95, and closed at ₹159.7.

This is a -4.37% slip from the previous day's closing price.

A total volume of 26,237 shares were traded at the close of the day’s session.

In the last one week, shares of INDRAPRASTHA MEDICAL CORP.LTD. have slipped by -11.43%.

INDRAPRASTHA MEDICAL CORP.LTD.'s Key Ratios

INDRAPRASTHA MEDICAL CORP.LTD. has a market cap of ₹10.20 billion, indicating a price to book ratio of 2.2337 and a price to sales ratio of 0.7878.

In the last 12-months INDRAPRASTHA MEDICAL CORP.LTD.’s revenue was ₹10.99 billion with a gross profit of ₹3.78 billion and an EBITDA of ₹1.51 billion. The EBITDA ratio measures INDRAPRASTHA MEDICAL CORP.LTD.'s overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, INDRAPRASTHA MEDICAL CORP.LTD.’s operating margin was 10.14% while its return on assets stood at 13.7% with a return of equity of 24.44%.

In Q1, INDRAPRASTHA MEDICAL CORP.LTD.’s quarterly earnings growth was a positive 30.5% while revenue growth was a positive 27%.

INDRAPRASTHA MEDICAL CORP.LTD.’s PE and PEG Ratio

Forward PE
0
Trailing PE
11.2715
PEG

Its diluted EPS in the last 12-months stands at ₹9.87 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into INDRAPRASTHA MEDICAL CORP.LTD.’s profitability.

INDRAPRASTHA MEDICAL CORP.LTD. stock is trading at a EV to sales ratio of 0.5741 and a EV to EBITDA ratio of 3.9802. Its price to sales ratio in the trailing 12-months stood at 0.7878.

INDRAPRASTHA MEDICAL CORP.LTD. stock pays annual dividends of ₹3 per share, indicating a yield of 2.28% and a payout ratio of 34.56%.

Balance sheet and cash flow metrics

Total Assets
₹5.55 billion
Total Liabilities
₹1.30 billion
Operating Cash Flow
₹0
Capital Expenditure
₹0
Dividend Payout Ratio
34.56%

INDRAPRASTHA MEDICAL CORP.LTD. ended 2024 with ₹5.55 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹5.55 billion while shareholder equity stood at ₹3.79 billion.

INDRAPRASTHA MEDICAL CORP.LTD. ended 2024 with ₹0 in deferred long-term liabilities, ₹1.30 billion in other current liabilities, in common stock, ₹0 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹522.60 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.

INDRAPRASTHA MEDICAL CORP.LTD.’s total current assets stands at ₹2.23 billion while long-term investments were ₹0 and short-term investments were ₹832.70 million. Its net receivables were ₹682.40 million compared to accounts payable of ₹981.80 million and inventory worth ₹84.50 million.

In 2024, INDRAPRASTHA MEDICAL CORP.LTD.'s operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, INDRAPRASTHA MEDICAL CORP.LTD. paid ₹0.35 in dividends in 2024.

Other key metrics

Current Trading Price
₹159.7
52-Week High
₹116
52-Week Low
₹56.651
Analyst Target Price

INDRAPRASTHA MEDICAL CORP.LTD. stock is currently trading at ₹159.7 per share. It touched a 52-week high of ₹116 and a 52-week low of ₹116. Analysts tracking the stock have a 12-month average target price of .

Its 50-day moving average was ₹139.23 and 200-day moving average was ₹98.1 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 5983.4% of the company’s stock are held by insiders while 2.4% are held by institutions.

Frequently Asked Questions About INDRAPRASTHA MEDICAL CORP.LTD.

The stock symbol (also called stock or share ticker) of INDRAPRASTHA MEDICAL CORP.LTD. is INDRAMEDCO

The IPO of INDRAPRASTHA MEDICAL CORP.LTD. took place on

Similar Industry Stocks (Medical Care Facilities)

Last Price
Chg
Chg%
Leslies Inc (LESL)
₹5.59
-0.09
-1.58%
Stevia Corp (STEV)
₹0
0
0%
₹1.51
0
0%
₹1.46
0.08
+5.8%
₹780.2
-24.95
-3.1%
₹226.05
-17.7
-7.26%
₹0.72
-0.06
-7.52%
Palamina Corp (PLMNF)
₹0.1
-0.01
-6.86%
₹1.82
-0.03
-1.62%
₹2.57
0.02
+0.78%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
₹0.14
0.07
+100%
₹0.12
0.04
+45.29%
₹0.96
0.05
+5.4%
₹1.34
-0.35
-20.71%
Humbl Inc (HMBL)
₹0
0
0%

Top Gainers

Last Price
Chg
Chg%
₹0
0
+172200%
₹0
0
+51200%
₹283
280.03
+9428.62%
₹11.2
10.57
+1667.68%
Latch Inc (LTCHW)
₹0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
₹0.19
-123.15
-99.85%
₹0
-0.11
-99.55%
₹0
-0
-97.96%
₹0
-0.01
-93.94%
₹0.01
-0.06
-92.24%

About

Indraprastha Medical Corporation Limited provides hospital services in India. It offers services primarily in the areas of anesthesiology, pediatric, elder care, genomic medicine, bariatric and metabolic surgery, bone marrow transplant, cancer, cardiac and cardiology, dermatology, dietetics and clinical nutrition, emergency care, endovascular surgery, endocrinology, ENT, cosmetic & plastic surgery, dental surgery, fetal medicine, gastroenterology and hepatology, laparoscopic surgery, gynecology and obstetrics, hyperbaric oxygen therapy, IVF, internal medicine, laboratory services, neonatology, nephrology, neurosciences, nuclear medicine, ophthalmology, orthopedic, pediatric urology and pediatric surgery, physiotherapy and rehabilitation, psychiatry and clinical psychology, radiology, respiratory sleep medicine and critical care, rheumatology, robotic surgery, spine surgery, transfusion medicine, transplant, and urology and andrology. The company was incorporated in 1988 and is based in New Delhi, India.

Address